A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

Background . Pancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was undertaken to determine the effect of gemcitabine by fixed-dose rate infusion (FDR), cisplatin and the COX-2 inhibitor, celecoxib, on the 6-month survival rate in patients with metastatic pancreatic cancer.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45281/1/10637_2005_Article_1028.pd